Daily9 小时
GSK RSV vaccine approved in Canada for adults aged 50-59 at increased risk
Mississauga: GSK's AREXVY (respiratory syncytial virus vaccine - recombinant, AS01E adjuvanted) has been approved in Canada ...
WSAW2 天
Doctors stress the importance of the RSV vaccine
The vaccine for this population is usually AREXVY. Receiving your vaccine doesn’t only help you, it helps the people around you stay healthy as well. “You know, I always say that an ounce of ...
Health Canada approves Moderna’s mRNA RSV vaccine, company says
The company says it expects the RSV vaccine — called mRESVIA — to be available in early 2025. There are two other vaccines ...
Canada approves Moderna's RSV vaccine for those age 60 and older, company says
Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years ...
Canada approves Moderna’s RSV vaccine, first of its kind for older adults
Health Canada has approved the vaccine, mRESVIA, for the prevention of lower respiratory tract disease in older adults, the company said.
来自MSN3 天
Year in Review: RSV
In June, the FDA expanded the approval of GSK's RSV vaccine (Arexvy) to include adults ages 50-59 at increased risk of lower ...
特朗普胜选会如何影响制药行业？
虽然一直以来共和党派别的总统当选会利好制药行业，但是此前特朗普暗示过会让小罗伯特·肯尼迪（JFK的侄子）这一反疫苗阴谋论人士在美国政府的食品健康相关职能中发挥重要作用。此前特朗普的竞选伙伴也暗示他可能会担任卫生与公共服务部（HHS）部长。届时疫苗商肯 ...
Pfizer, GSK, Moderna struggle in a shrinking RSV vaccine market
Q3 results confirms that the U.S. vaccine market for respiratory syncytial virus (RSV), led by Pfizer (PFE) and GSK (GSK), is ...
The Pharma Letter5 天
GSK’s Arexvy receives expanded approval in Canada
GSK’s Arexvy has received expanded approval in Canada for preventing RSV-related lower respiratory tract disease in adults ...
Pharmaceutical Technology5 天
GSK’s RSV vaccine approved in Canada for adults aged 50 to 59
GSK has received approval for its vaccine, AREXVY, in Canada to prevent LRTD caused by RSV in adults aged 50 to 59 years.
指南调整后，葛兰素史克RSV疫苗销售额暴跌74%
去年，RSV疫苗技惊四座；今年，却迅速回落。日前，葛兰素史克发布财报，其RSV疫苗Arexvy第三季度销售额同比下降74%，销售额为1.88亿英镑，折合2.4亿美元。 最核心的，是美国疾病控制与预防中心（CDC）的免疫接种建议范围缩小。此前，RSV疫苗被建议用于60岁以上的老年人接种。而在今年6月份，美国CDC调整了接种人群的建议。调整之后，范围大幅缩小，局限于： ...